Effectiveness of a second course of okt3 monoclonal anti-t cell antibody for treatment of renal allograft rejection

Douglas J. Norman; Charles F. Shield; Karen R. Henell; Jess Kimball; John M. Barry; William M. Bennett; Michael Leone

doi:10.1097/00007890-198810000-00011

Effectiveness of a second course of okt3 monoclonal anti-t cell antibody for treatment of renal allograft rejection

Douglas J. Norman, Charles F. Shield, Karen R. Henell, Jess Kimball, John M. Barry, William M. Bennett, Michael Leone

Research output: Contribution to journal › Article › peer-review

60 Scopus citations

Abstract

A second course of OKT3 monoclonal anti-T cell antibody was given to 21 recipients of kidney transplants. Rejections reversed in 43% of patients in whom 95% of rejections had reversed with their initial OKT3 course. Reversal was highly dependent upon the timing of rejection, anti-OKT3 antibody production, and T cell CD3 modulation. Rejections treated greater than 90 days after transplantation were resistant to OKT3 reversal. High-titer anti-OKT3 antibodies prevented OKT3 reversal of rejection, and effective CD3 (the cell surface target of OKT3) modulation was necessary for successful OKT3 reversal of rejection. Reexposure to OKT3 further stimulated anti-OKT3 antibody production and broadened the specificity of the antibodies produced. OKT3 can effectively and safely be used a second time for treatment of early T cell—mediated renal allograft rejections if high-titer anti-OKT3 antibodies have not been made.

Original language	English (US)
Pages (from-to)	523-529
Number of pages	7
Journal	Transplantation
Volume	46
Issue number	4
DOIs	https://doi.org/10.1097/00007890-198810000-00011
State	Published - Oct 1988

ASJC Scopus subject areas

Transplantation

Access to Document

10.1097/00007890-198810000-00011

Cite this

@article{d573f0c3a85144c8a1fe3c1b44a1b46a,

title = "Effectiveness of a second course of okt3 monoclonal anti-t cell antibody for treatment of renal allograft rejection",

abstract = "A second course of OKT3 monoclonal anti-T cell antibody was given to 21 recipients of kidney transplants. Rejections reversed in 43% of patients in whom 95% of rejections had reversed with their initial OKT3 course. Reversal was highly dependent upon the timing of rejection, anti-OKT3 antibody production, and T cell CD3 modulation. Rejections treated greater than 90 days after transplantation were resistant to OKT3 reversal. High-titer anti-OKT3 antibodies prevented OKT3 reversal of rejection, and effective CD3 (the cell surface target of OKT3) modulation was necessary for successful OKT3 reversal of rejection. Reexposure to OKT3 further stimulated anti-OKT3 antibody production and broadened the specificity of the antibodies produced. OKT3 can effectively and safely be used a second time for treatment of early T cell—mediated renal allograft rejections if high-titer anti-OKT3 antibodies have not been made.",

author = "Norman, {Douglas J.} and Shield, {Charles F.} and Henell, {Karen R.} and Jess Kimball and Barry, {John M.} and Bennett, {William M.} and Michael Leone",

year = "1988",

month = oct,

doi = "10.1097/00007890-198810000-00011",

language = "English (US)",

volume = "46",

pages = "523--529",

journal = "Transplantation",

issn = "0041-1337",

publisher = "Lippincott Williams and Wilkins",

number = "4",

}

TY - JOUR

T1 - Effectiveness of a second course of okt3 monoclonal anti-t cell antibody for treatment of renal allograft rejection

AU - Norman, Douglas J.

AU - Shield, Charles F.

AU - Henell, Karen R.

AU - Kimball, Jess

AU - Barry, John M.

AU - Bennett, William M.

AU - Leone, Michael

PY - 1988/10

Y1 - 1988/10

N2 - A second course of OKT3 monoclonal anti-T cell antibody was given to 21 recipients of kidney transplants. Rejections reversed in 43% of patients in whom 95% of rejections had reversed with their initial OKT3 course. Reversal was highly dependent upon the timing of rejection, anti-OKT3 antibody production, and T cell CD3 modulation. Rejections treated greater than 90 days after transplantation were resistant to OKT3 reversal. High-titer anti-OKT3 antibodies prevented OKT3 reversal of rejection, and effective CD3 (the cell surface target of OKT3) modulation was necessary for successful OKT3 reversal of rejection. Reexposure to OKT3 further stimulated anti-OKT3 antibody production and broadened the specificity of the antibodies produced. OKT3 can effectively and safely be used a second time for treatment of early T cell—mediated renal allograft rejections if high-titer anti-OKT3 antibodies have not been made.

AB - A second course of OKT3 monoclonal anti-T cell antibody was given to 21 recipients of kidney transplants. Rejections reversed in 43% of patients in whom 95% of rejections had reversed with their initial OKT3 course. Reversal was highly dependent upon the timing of rejection, anti-OKT3 antibody production, and T cell CD3 modulation. Rejections treated greater than 90 days after transplantation were resistant to OKT3 reversal. High-titer anti-OKT3 antibodies prevented OKT3 reversal of rejection, and effective CD3 (the cell surface target of OKT3) modulation was necessary for successful OKT3 reversal of rejection. Reexposure to OKT3 further stimulated anti-OKT3 antibody production and broadened the specificity of the antibodies produced. OKT3 can effectively and safely be used a second time for treatment of early T cell—mediated renal allograft rejections if high-titer anti-OKT3 antibodies have not been made.

UR - http://www.scopus.com/inward/record.url?scp=0023791604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023791604&partnerID=8YFLogxK

U2 - 10.1097/00007890-198810000-00011

DO - 10.1097/00007890-198810000-00011

M3 - Article

C2 - 3140448

AN - SCOPUS:0023791604

SN - 0041-1337

VL - 46

SP - 523

EP - 529

JO - Transplantation

JF - Transplantation

IS - 4

ER -

Effectiveness of a second course of okt3 monoclonal anti-t cell antibody for treatment of renal allograft rejection

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this